Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

1.

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM, Abate-Shen C.

Cancer Res. 2012 Sep 1;72(17):4483-93. doi: 10.1158/0008-5472.CAN-12-0283. Epub 2012 Jul 19.

PMID:
22815528
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

PMID:
23167739
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX.

Mol Cancer Ther. 2013 Aug;12(8):1665-75. doi: 10.1158/1535-7163.MCT-13-0159. Epub 2013 May 20.

PMID:
23689832
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.

Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM.

Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18.

PMID:
22614157
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.

Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.

Int J Cancer. 2013 Nov;133(9):2065-76. doi: 10.1002/ijc.28214. Epub 2013 May 29.

PMID:
23588885
[PubMed - indexed for MEDLINE]
6.

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H.

Mol Cancer Ther. 2010 Jul;9(7):1956-67. doi: 10.1158/1535-7163.MCT-09-1012. Epub 2010 Jun 22.

PMID:
20571069
[PubMed - indexed for MEDLINE]
Free Article
7.

Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways.

Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, Chen G, Luo J, Shi X.

PLoS One. 2012;7(10):e47516. doi: 10.1371/journal.pone.0047516. Epub 2012 Oct 18.

PMID:
23094058
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.

Clin Cancer Res. 2012 May 1;18(9):2534-44. doi: 10.1158/1078-0432.CCR-11-1407. Epub 2012 Feb 14.

PMID:
22338016
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.

Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C.

J Clin Invest. 2008 Sep;118(9):3051-64. doi: 10.1172/JCI34764.

PMID:
18725989
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.

Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7.

PMID:
23468082
[PubMed - indexed for MEDLINE]
11.

Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.

Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, Kumar S.

PLoS One. 2012;7(11):e50005. doi: 10.1371/journal.pone.0050005. Epub 2012 Nov 21.

PMID:
23185517
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.

PMID:
23954373
[PubMed - indexed for MEDLINE]
13.

The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.

Ji D, Zhang Z, Cheng L, Chang J, Wang S, Zheng B, Zheng R, Sun Z, Wang C, Zhang Z, Liu R, Zhang X, Liu X, Wang X, Li J.

PLoS One. 2014 Jan 9;9(1):e85116. doi: 10.1371/journal.pone.0085116. eCollection 2014.

PMID:
24416349
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.

Subramaniam D, Periyasamy G, Ponnurangam S, Chakrabarti D, Sugumar A, Padigaru M, Weir SJ, Balakrishnan A, Sharma S, Anant S.

Mol Cancer Ther. 2012 Jul;11(7):1598-608. doi: 10.1158/1535-7163.MCT-12-0102. Epub 2012 Apr 24.

PMID:
22532602
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

PMID:
23966621
[PubMed - indexed for MEDLINE]
Free Article
16.

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.

Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T.

Mol Cancer Ther. 2011 Jun;10(6):1059-71. doi: 10.1158/1535-7163.MCT-10-0792. Epub 2011 Apr 11.

PMID:
21482695
[PubMed - indexed for MEDLINE]
Free Article
17.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

PMID:
22559167
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM.

Oncotarget. 2012 Aug;3(8):811-23.

PMID:
22885370
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

PMID:
15585641
[PubMed - indexed for MEDLINE]
Free Article
20.

Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B.

J Biol Chem. 2012 Jul 6;287(28):23698-709. doi: 10.1074/jbc.M112.358713. Epub 2012 May 22.

PMID:
22619175
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk